Compare Unity Software Inc (U) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Unity Software Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Unity Software Inc trades at $46.76 (market cap $20.20B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.3× Unity Software Inc's market cap, and Unity Software Inc is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Unity Software Inc for 50 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| U | VRTX | |
|---|---|---|
Market Cap | $20.20B | $127.55B |
Volume | 15,432,191 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $49.47 | $557.96 |
52-Week Low | $17.13 | $407.37 |
Typical Hold Time | 50 Days | 120 Days |
Enterprise Value | $20.08B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Unity Software (U) trades at $46.88, up 3.17% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $46.54. The company reported revenue of $1.85 billion for 2025, with improving net loss margins from -66.22% in 2022 to -21.78% in 2025. Recent news highlights momentum from Meta VR Glasses support and positive analyst coverage, though the stock shows overbought RSI signals near-term.
The stock presents a growth opportunity driven by strategic revenue expansion and margin improvements, but carries risks from persistent net losses, high valuation multiples, and competitive pressures in the gaming engine market. Institutional ownership trends and insider sales require monitoring for sentiment shifts.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
